Gadoteridol
Prohance (gadoteridol) is a small molecule pharmaceutical. Gadoteridol was first approved as Prohance on 1992-11-16.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Prohance, Prohance multipack
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| prohance | New Drug Application | 2022-10-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| A9576 | Injection, gadoteridol, (prohance multipack), per ml |
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognition | D003071 | EFO_0003925 | — | — | — | 1 | — | 1 | |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | — | 1 | — | 1 | 2 |
| Diagnostic imaging | D003952 | — | — | 1 | — | — | 1 | ||
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | 2 | 3 |
| Glioblastoma | D005909 | EFO_0000515 | 1 | — | — | — | 1 | 2 | |
| Glioma | D005910 | EFO_0000520 | 1 | — | — | — | — | 1 | |
| Astrocytoma | D001254 | EFO_0000271 | 1 | — | — | — | — | 1 | |
| Chronic progressive multiple sclerosis | D020528 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GADOTERIDOL |
| INN | gadoteridol |
| Description | Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance. Gadoteridol was first approved for use in the United States in 1992.
|
| Classification | Small molecule |
| Drug class | gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3] |
Identifiers
| PDB | — |
| CAS-ID | 120066-54-8 |
| RxCUI | 25483 |
| ChEMBL ID | CHEMBL1200593 |
| ChEBI ID | 31643 |
| PubChem CID | 60714 |
| DrugBank | DB00597 |
| UNII ID | 0199MV609F (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,018 documents
View more details
Safety
Black-box Warning
Black-box warning for: Prohance
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,842 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more